P444 A case series of pre-exposure prophylaxis failures in men using event-based-dosing in london, UK. (14th July 2019)

• Record Type: Journal Article
• Authors: Fitzgerald, Naomi; Nori, Achyuta
• Is Part Of: Sexually transmitted infections. Volume 95(2019)Supplement 1
• Page Start: A209
• Page End: A209
• Publication Date: 2019-07-14
• Subjects: ART -- PrEP; Sexually transmitted diseases -- Periodicals; HIV infections -- Periodicals; 616.951005
• DOI: 10.1136/sextrans-2019-sti.528
• Languages: English
• ISSNs: 1368-4973

Abstract

Abstract : Background: British guidelines recommend both event-based dosing (EBD) and daily dosing of combined tenofovir/emtricitabine (TDF/FTC) for HIV pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM). Access to PrEP in the UK is either through a clinical study with limited capacity or by purchasing online. Dosing schedules are usually self-selected, often without access to professional advice or evidenced-based information. Non-daily dosing is popular as it is believed to be less toxic and more affordable than daily dosing. Methods: We describe three cases of HIV acquisition despite use of PrEP. Results: All were MSM and had a negative antigen/antibody HIV tests at 3 months of use. Case 1 switched to EBD after one month of daily PrEP. After several months he switched back to daily PrEP and had a positive HIV-1 antibody test six weeks later. Case 2 switched to EBD after 5 months of daily PrEP due to lower frequency of sex. He reported excellent adherence. He had a positive HIV-1 antibody test 4 months later. Case 3 was taking EBD PrEP for a total of 9 months. He had a positive HIV-1 antibody 5 months after his last negative HIV test. This was two months after his last episode of condomless sex. He reported occasional late dosing and some use of recreational drugs. Conclusion: It is likely that all three cases became infected while taking event-based PrEP. Two cases switched between daily and EBD due to lower self-perceived risk of HIV or frequency of sex. It is not clear if this may have affected PrEP efficacy. Evidence for effective EBD is strongly dependent on adherence and timing of doses. It is therefore vital that PrEP provision includes objective HIV risk assessment, adherence support and evidence-based dosing information to optimise efficacy. Disclosure: No significant relationships.